Jun 18, 2024
Prompted by a Client’s questions about Category M and the formula that goes behind it to drive Pharmacy profitability, we asked Charles Joynson, WaveData MD, to have a closer look at Category M to see if he can make any sense of it. Initially that we assumed that the...
Feb 8, 2024
WaveData conducted a comparison of the average market prices given to accounts (pharmacies and dispensing doctors) by respiratory product manufacturers. The average discounts given over a 10 year period are very consistent at 9%, which probably reflects the underlying...
Nov 9, 2023
It would seem sensible to assume that profitable products are less likely to suffer shortages, concessions and price spikes than products where profit is hard to come by. Charles Joynson, WaveData MD, compared the reimbursement price and the average market price for...
Oct 10, 2023
Charles Joynson, WaveData MD, drilled into this to see where the increase is coming from, demonstrating that it’s a mixture of parallel import and generics which are driving the rise. – Parallel imports have risen from £22.73 in Sept 2013 to 26.24 in August...
Aug 24, 2023
Normally we expect branded devices to maintain their pharmacy purchase prices over long periods of time. However, here this is not the case. Charles Joynson, WaveData MD investigates further. Looking at the long term market price trends of Freestyle Optium Test Strips...
Aug 24, 2022
At Wavedata we have always believed that product complexity and manufacturing cost was the limiting factor on how quickly prices would fall after generic launch. However, is this correct? To clarify this Wavedata looked at 414 solid dose, combined, liquids, devices...
